P1071 - Characterizing COVID-19 in Relation to Acute Pancreatitis

Neal Shah, DO¹, Anthony Razzano, MD², Meredith Akerman, MS³, Jasmin Divers, PhD⁴, James Grendell, MD^3
1NYU Langone Health - Long Island, Mineola, NY; ²NYU Langone Hospital - Long Island, Mineola, NY; ³New York University Langone Medical Center, Mineola, NY; ⁴NYU Langone Hospital, Mineola, NY

Introduction: The purpose of this study is to evaluate the relationship between patients with a history acute pancreatitis and tested for COVID-19 across all of NYU Langone Health system from 2/28/2020 to 6/24/2020 in order to ascertain the following information in regards to the novel coronavirus (COVID-19) and to provide clinicians greater information with hope of improving clinical outcomes.

Methods: Using billing codes, other patient demographics, and our COVID-19 Datamart we obtained a list of patients who had a history of acute pancreatitis and tested for COVID-19. Charts were reviewed manually to review various metrics. Descriptive statistics (medians [25^th, 75^th percentiles] for continuous variables and frequencies and percentages for categorical variables) were calculated separately for acute pancreatitis patients that were COVID positive vs. COVID negative. The Mann-Whitney test was used to test for differences between the groups for continuous variables, and the chi-square or Fisher’s exact test was used for categorical variables. A result was considered statistically significant at the p< 0.05 level of significance. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results: A total of 391 patients with a history of acute pancreatitis were tested for COVID in the inpatient setting. Our study contains the largest sample of patients to date. 74 patients were COVID positive (18.9%). Weighted Elixhauser score (AHRQ) and Charlson Comorbidity Index were equivocal when comparing the past medical histories of our two patient populations. Significant data was defined as p < 0.05. A significantly greater number of COVID negative patients were current smokers. However, COVID positive patients were more likely to have a history of diabetes with complications, coagulopathy, fluid and electrolyte disorders, and other neurological disorders. COVID positive patients took a higher percentage of steroid use (hydrocortisone and methylprednisolone). Length of stay and death rates were significantly worse for COVID positive patient. Inconsistent lab draws made comparisons challenging.

Discussion: Prevalence of COVID-19 among patients with prior acute pancreatitis is 18.9% which is significantly higher than the population-weighted prevalence of SARS-CoV-2 positive serology in our background population of 6.9. Need for further studies to be conducted in patients with pancreatitis and COVID to help risk stratify patients for improved clinical outcomes.


Disclosures:
Neal Shah indicated no relevant financial relationships.
Anthony Razzano indicated no relevant financial relationships.
Meredith Akerman indicated no relevant financial relationships.
Jasmin Divers indicated no relevant financial relationships.
James Grendell indicated no relevant financial relationships.


Neal Shah, DO¹, Anthony Razzano, MD², Meredith Akerman, MS³, Jasmin Divers, PhD⁴, James Grendell, MD³. P1071 - Characterizing COVID-19 in Relation to Acute Pancreatitis, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.